test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/6911

Title: Use of liposomal amphotericin B in bone marrow transplant.
Authors: Sastry, P. S. R. K.
Parikh, P. M.
Kulkarni, P. S.
Bhagwat, R.
Gadade, H.
Keywords: Bone marrow transplant, fungal infections, liposomal amphotericin B
Issue Date: 31-Dec-2005
Publisher: Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
Citation: Journal of Postgraduate Medicine (ISSN: 0972-2823) Vol 51 Num 5s1
Abstract: Increasing number of transplants worldwide has resulted in an increase in the incidence of fungal infections. Prolonged neutropenia, immunosuppression and graft vs. host disease all result in high predisposition to fungal infections. The likelihood of developing a fungal infection increases with the severity and duration of neutropenia, which, in the case of cancer or chemotherapy for the treatment of hematological malignancies, can range from a few days to several weeks. Invasive fungal infections are difficult to diagnose and neutropenic patients with fever often receive empirical antifungal therapy. This provides a rationale for the prophylactic use of antifungal agents. The empirical use of liposomal amphotericin B has overcome some of the difficulties usually found in this setting. The majority of clinical efficacy data related to liposomal amphotericin B are derived from compassionate use studies and case series. The major advantage of these liposomal formulations of amphotericin B is a reduction in amphotercin toxicity. Use of liposomal amphotericin has been shown to be a cost-effective approach abroad and the same has been our experience also. Commercially ambisome and Fungisome are the only products that contain true liposomes. Unlike ambisome, which needs to be used in dose of 3 mg/kg/day FungisomeTM is effective in the dose of 1-3 mg/kg bodyweight. The Indian liposomal preparation has shown to be safe and effective used in over 150 transplant patients in our experience. We conclude that the liposomal amphotericin is better-tolerated and also gives better responses in documented fungal infections.
URI: http://hdl.handle.net/1807/6911
Other Identifiers: http://www.bioline.org.br/abstract?id=jp05133
Rights: Copyright 2005 Journal of Postgraduate Medicine.
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
jp05133.pdf242.6 kBAdobe PDF
View/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft